389 related articles for article (PubMed ID: 34149718)
1. Immunotherapy in Acral and Mucosal Melanoma: Current Status and Future Directions.
Mao L; Qi Z; Zhang L; Guo J; Si L
Front Immunol; 2021; 12():680407. PubMed ID: 34149718
[TBL] [Abstract][Full Text] [Related]
2. Targeted Therapy and Immunotherapy for Melanoma in Japan.
Namikawa K; Yamazaki N
Curr Treat Options Oncol; 2019 Jan; 20(1):7. PubMed ID: 30675668
[TBL] [Abstract][Full Text] [Related]
3. Management of Acral and Mucosal Melanoma: Medical Oncology Perspective.
Jung S; Johnson DB
Oncologist; 2022 Aug; 27(8):703-710. PubMed ID: 35640549
[TBL] [Abstract][Full Text] [Related]
4. Translational pathology, genomics and the development of systemic therapies for acral melanoma.
Chen YA; Teer JK; Eroglu Z; Wu JY; Koomen JM; Karreth FA; Messina JL; Smalley KSM
Semin Cancer Biol; 2020 Apr; 61():149-157. PubMed ID: 31689494
[TBL] [Abstract][Full Text] [Related]
5. Distinct genomic traits of acral and mucosal melanomas revealed by targeted mutational profiling.
Zou Z; Ou Q; Ren Y; Lv Q; Qin L; Zhao L; Su S; Wu X; Bao H; Wang A; Zhu D; Wang X; Shao YW; Liu B
Pigment Cell Melanoma Res; 2020 Jul; 33(4):601-611. PubMed ID: 31944535
[TBL] [Abstract][Full Text] [Related]
6. Detecting copy number alterations of oncogenes in cell-free DNA to monitor treatment response in acral and mucosal melanoma.
Mikoshiba A; Ashida A; Sakaizawa K; Kiniwa Y; Okuyama R
J Dermatol Sci; 2020 Mar; 97(3):172-178. PubMed ID: 31987696
[TBL] [Abstract][Full Text] [Related]
7. Diagnosis and Management of Acral Lentiginous Melanoma.
Nakamura Y; Fujisawa Y
Curr Treat Options Oncol; 2018 Jun; 19(8):42. PubMed ID: 29951919
[TBL] [Abstract][Full Text] [Related]
8. Variable indoleamine 2,3-dioxygenase expression in acral/mucosal melanoma and its possible link to immunotherapy.
Iga N; Otsuka A; Hirata M; Kataoka TR; Irie H; Nakashima C; Matsushita S; Uchi H; Yamamoto Y; Funakoshi T; Fujisawa Y; Yoshino K; Fujimura T; Hata H; Ishida Y; Kabashima K
Cancer Sci; 2019 Nov; 110(11):3434-3441. PubMed ID: 31509303
[TBL] [Abstract][Full Text] [Related]
9. Treatment of acral and mucosal melanoma: Current and emerging targeted therapies.
Zhang J; Tian H; Mao L; Si L
Crit Rev Oncol Hematol; 2024 Jan; 193():104221. PubMed ID: 38036156
[TBL] [Abstract][Full Text] [Related]
10. Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma.
Klemen ND; Wang M; Rubinstein JC; Olino K; Clune J; Ariyan S; Cha C; Weiss SA; Kluger HM; Sznol M
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32209601
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy Options for Acral Melanoma, A fast-growing but Neglected Malignancy.
Gajón JA; Juarez-Flores A; De León Rodríguez SG; Aguilar Flores C; Mantilla A; Fuentes-Pananá EM; Bonifaz LC
Arch Med Res; 2022 Dec; 53(8):794-806. PubMed ID: 36460547
[TBL] [Abstract][Full Text] [Related]
12. Extracutaneous Melanoma.
Carvajal R; Maniar R
Hematol Oncol Clin North Am; 2021 Feb; 35(1):85-98. PubMed ID: 33759775
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of anti-PD-1 agents in acral and mucosal melanoma.
Shoushtari AN; Munhoz RR; Kuk D; Ott PA; Johnson DB; Tsai KK; Rapisuwon S; Eroglu Z; Sullivan RJ; Luke JJ; Gangadhar TC; Salama AK; Clark V; Burias C; Puzanov I; Atkins MB; Algazi AP; Ribas A; Wolchok JD; Postow MA
Cancer; 2016 Nov; 122(21):3354-3362. PubMed ID: 27533633
[TBL] [Abstract][Full Text] [Related]
14. Primary mucosal melanomas: a comprehensive review.
Mihajlovic M; Vlajkovic S; Jovanovic P; Stefanovic V
Int J Clin Exp Pathol; 2012; 5(8):739-53. PubMed ID: 23071856
[TBL] [Abstract][Full Text] [Related]
15. KIT amplification and gene mutations in acral/mucosal melanoma in Korea.
Yun J; Lee J; Jang J; Lee EJ; Jang KT; Kim JH; Kim KM
APMIS; 2011 Jun; 119(6):330-5. PubMed ID: 21569090
[TBL] [Abstract][Full Text] [Related]
16. Large-scale analysis of KIT aberrations in Chinese patients with melanoma.
Kong Y; Si L; Zhu Y; Xu X; Corless CL; Flaherty KT; Li L; Li H; Sheng X; Cui C; Chi Z; Li S; Han M; Mao L; Lu A; Guo J
Clin Cancer Res; 2011 Apr; 17(7):1684-91. PubMed ID: 21325067
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint inhibitor-based therapy for advanced acral and mucosal melanoma.
Mori T; Izumi T; Doi R; Kamimura A; Takai S; Teramoto Y; Nakamura Y
Exp Dermatol; 2023 Mar; 32(3):276-289. PubMed ID: 36477933
[TBL] [Abstract][Full Text] [Related]
18. Multidisciplinary approach and treatment of acral and mucosal melanoma.
Fortuna A; Amaral T
Front Oncol; 2024; 14():1340408. PubMed ID: 38469235
[TBL] [Abstract][Full Text] [Related]
19. Targeted Genomic Profiling of Acral Melanoma.
Yeh I; Jorgenson E; Shen L; Xu M; North JP; Shain AH; Reuss D; Wu H; Robinson WA; Olshen A; von Deimling A; Kwok PY; Bastian BC; Asgari MM
J Natl Cancer Inst; 2019 Oct; 111(10):1068-1077. PubMed ID: 30657954
[TBL] [Abstract][Full Text] [Related]
20. Clinical and genetic analysis of melanomas arising in acral sites.
Zaremba A; Murali R; Jansen P; Möller I; Sucker A; Paschen A; Zimmer L; Livingstone E; Brinker TJ; Hadaschik E; Franklin C; Roesch A; Ugurel S; Schadendorf D; Griewank KG; Cosgarea I
Eur J Cancer; 2019 Sep; 119():66-76. PubMed ID: 31419753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]